Month: November 2022

Chitosan/heparin blends in ionic liquid produce polyelectrolyte complexes that quickly adsorb citrate-capped silver nanoparticles, forming bactericidal composites was written by Souza, Paulo R.;Vilsinski, Bruno H.;de Oliveira, Ariel C.;Berton, Sharise B. R.;Nunes, Catia S.;Kipper, Matt J.;Schrekker, Henri S.;Martins, Alessandro F.;Muniz, Edvani C.. And the article was included in Journal of Molecular Liquids in 2021.Formula: C10H20N2O4S The following contents are mentioned in the article:

We present chitosan (CHT)/heparin (HP) polyelectrolyte complexes (PECs) that quickly adsorb citrate-capped silver nanoparticles (AgNPs). CHT/HP blends in ionic liquid ([HMIm][HSO4]) form durable PECs after precipitation in water. CHT/HP PECs have pos. Zeta potentials (higher than +20 mV). They adsorb citrate-capped AgNPs (Zeta potential of – 12.25 mV) synthesized from Turkevichs method. PEC/AgNPs composites are characterized by spectroscopic, thermal, and microscopy analyses. AgNPs on the PEC surfaces are confirmed by transmission electron microscopy. PECs adsorb AgNPs from aqueous suspensions, achieving 鈮?95% of removal (17.18渭g of AgNPs per mg of PEC) after only 10 min. The pseudo-second-order kinetic model adjusted well to the exptl. data. The PECs release approx. 11.80渭g/mg Ag+ (66%) compared to the initial adsorbed AgNPs content (17.18渭g/mg) after 7200 min at pH 2.0. The PECs present low swelling degrees (between 130 and 150%), supporting high stability in water. PEC/AgNPs composites promote significant bactericidal activity toward Staphylococcus aureus and Escherichia coli between 0.25 and 0.5 mg/mL. This study shows a new strategy to create hybrid polysaccharide/AgNPs composites. PECs can stabilize the AgNPs and release Ag+ ions, supporting antimicrobial materials. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Formula: C10H20N2O4S).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Formula: C10H20N2O4S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Electrochemical properties of imidazolium salt electrolytes for electrochemical capacitor applications was written by McEwen, Alan B.;Ngo, Elen L.;LeCompte, Karen;Goldman, Jay L.. And the article was included in Journal of the Electrochemical Society in 1999.Product Details of 157310-73-1 The following contents are mentioned in the article:

The specific ionic conductivity, dynamic viscosity, and electrochem. stability of several imidazolium salts are reported as neat ionic liquids and their solutions in several organic solvents. The temperature dependence of conductivity and viscosity are analyzed for 1-ethyl-3-methylimidazolium (EMI⁺) and 1,2-dimethyl-3-n-propylimidazolium (DMPI⁺) salts, and the influence of bis(trifluoromethylsulfonyl)imide (Im^–), bis(perfluoroethylsulfonyl)imide (Beti^–), hexafluoroarsenate (AsF₆^–), hexafluorophosphate (PF₆^–), and tetrafluoroborate (BF₄^–) on these properties are discussed. These imidazolium salts make possible electrolytes with high concentration (>3 M), high room temperature conductivity (up to 60 mS/cm), and a wide window of stability (>4 V at 20 VA/cm²). Differential scanning calorimetric results confirm a large glass phase for the ionic liquids, with substantial (>80掳) supercooling. Thermal gravimetric results indicate the imidazolium salts with Im^– and Beti^– anions to be thermally more stable than the Li salt analogs. The Vogel-Tammann-Fulcher interpretation accurately describes the conductivity temperature dependence. This study involved multiple reactions and reactants, such as 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1Product Details of 157310-73-1).

1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Product Details of 157310-73-1

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma was written by Mateos, Maria-Victoria;Weisel, Katja;De Stefano, Valerio;Goldschmidt, Hartmut;Delforge, Michel;Mohty, Mohamad;Cavo, Michele;Vij, Ravi;Lindsey-Hill, Joanne;Dytfeld, Dominik;Angelucci, Emanuele;Perrot, Aurore;Benjamin, Reuben;van de Donk, Niels W. C. J.;Ocio, Enrique M.;Scheid, Christof;Gay, Francesca;Roeloffzen, Wilfried;Rodriguez-Otero, Paula;Broijl, Annemiek;Potamianou, Anna;Sakabedoyan, Caline;Semerjian, Maria;Keim, Sofia;Strulev, Vadim;Schecter, Jordan M.;Vogel, Martin;Wapenaar, Robert;Nesheiwat, Tonia;San-Miguel, Jesus;Sonneveld, Pieter;Einsele, Hermann;Moreau, Philippe. And the article was included in Leukemia in 2022.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, 鈮? prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 mo (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The structures, photoluminescence and photocatalytic properties of two types of iodocuprate hybrids was written by Lin, Chong-Yang;Zhang, Di;Sun, Xin-Yuan;Wei, Li;Xue, Zhen-Zhen;Pan, Jie;Wang, Guo-Ming. And the article was included in Inorganic Chemistry Communications in 2018.Electric Literature of C11H9N5 The following contents are mentioned in the article:

Two new Cu(I)-iodide clusters driven by 3,5-bis(imidazole-1-yl)pyridine (bip), [(H₂bip)₂Cu₅I₉] (1) and [H₂bip]₂[Cu₃I₇] (2), were prepared via modulating organic/inorganic ratio at room temperature Compound 1 presents a zero-dimensional structure constituting of [Cu₄I₈]^4- and [(H₂bip)₂CuI₂]³⁺ two different subunits. Compound 2 features a discrete [Cu₃I₇]^4- anionic cluster, which is the 1st isolated iodocuprate cluster with protonated bip as structure-directing agent (SDA). The structural diversity of 1 and 2 mainly stems from the distinct role of bip during the crystallization Meanwhile, the reaction ratio here also plays an essential role on the fabrication of two structures. The solid-state luminescence bands of 1 and 2 were studied between 499 and 78 K. Both of them exhibit yellow luminescence, and their intensities increase gradually upon cooling. What is more, photocatalytic properties of 1 and 2 were studied. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Electric Literature of C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Electric Literature of C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Spectroscopic, quantum mechanical, electronic excitation properties (Ethanol solvent), DFT investigations and molecular docking analysis of an anti-cancer drug Bendamustine was written by Ramana, P. Venkata;Sundius, Tom;Muthu, S.;Mouli, K. Chandra;Krishna, Y. Rama;Prasad, K. Venkata;Devi, R. Niranjana;Irfan, Ahmad;Santhamma, C.. And the article was included in Journal of Molecular Structure in 2022.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:

In this investigation, optimization geometry of the mol., FT-IR, FT-Raman, and UV-Vis spectra, vibrational frequencies, assigning of suitable vibrational modes of Bendamustine (an anti-cancer drug) were summarised on the grounds of distribution of potential energy. Spectroscopic investigations are attempted by employing DFT/B3LYP with 6-311++G (d, p) level. The output of the computations was implemented to model the spectra of the Bendamustine, which agrees well with the recorded spectra. The TDFT had been utilized to compute the strengths of oscillators. To ascertain the transfer of charge inside the mol. HOMO and LUMO analytics have been utilized. The NBO investigation has been employed to verify the stability of the mol. by observing internal charge transfer, hyperconjugation, and energy of stabilization. Mol. electrostatic potential and Mulliken’s charges were thoroughly studied by using DFT methods. The NLO characteristics of the title drug mol. were investigated with B3LYP and HF basis functionals. The reactive sites and reactivity of the title drug mol. have been extensively studied with help of condensed Fukui functions and global descriptors. The mol. docking investigations of the title drug mol. were executed with the DNA binding protein of Cellular Tumor Antigen P53. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).HPLC of Formula: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties was written by Jiang, Xindong;Shen, Tianxiang;Jin, Zhaolei;Li, Chunlong;Li, Qingpo;Qiu, Weigen;Cui, Yannan;Han, Zhihui;Hou, Xuemei;You, Jian. And the article was included in Life Sciences in 2021.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

At present, little information on the biopharmaceutical behavior of proton pump inhibitors (PPIs) describing their absorption and biodistribution in vivo has been reported because the extreme instability of PPIs in the gastrointestinal environment makes it difficult to analyze such behavior. In this work, a modified rat in situ intestinal perfusion model was employed to investigate absorption in the gastrointestinal tract and subsequent biodistribution of several PPIs (ilaprazole, esomeprazole and rabeprazole), which have different physicochem. properties. Our data indicated that PPIs exhibited significantly enhanced absorption rates in the whole intestine, including the duodenum, jejunum, ileum and colon, corresponding to the increase in the oil-water partition coefficient (LogP). PPIs and corresponding salt types showed no obvious differences in absorption, implying that solubility changes in the PPI have little effect on its absorption in the gastrointestinal tract. Among these PPIs, ilaprazole presented a more stable intestinal absorption behavior, as well as more distribution and longer residence time in the stomach by HPLC-MS/MS anal. and radioactivity counts after 14C radiolabelling. These results may be useful information for PPI optimization and oral formulation design. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data was written by Sehn, Laurie H.;Hertzberg, Mark;Opat, Stephen;Herrera, Alex F.;Assouline, Sarit;Flowers, Christopher R.;Kim, Tae Min;McMillan, Andrew;Ozcan, Muhit;Safar, Violaine;Salles, Gilles;Ku, Grace;Hirata, Jamie;Chang, Yi Meng;Musick, Lisa;Matasar, Matthew J.. And the article was included in Blood Advances in 2022.Application of 16506-27-7 The following contents are mentioned in the article:

Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of the GO29365 study. After the randomized phase, 106 addnl. patients received pola + BR in a single-arm extension cohort. We report updated results from the randomized arms and results of the extension cohort. In this phase 1b/2 study, patients with R/R DLBCL who were transplant ineligible received up to six 21-day cycles of pola + BR or BR. The primary end point of the randomized arms was the complete response (CR) rate at end of treatment. Primary objectives of the extension cohort were safety, pharmacokinetic profile, and efficacy of pola + BR. As of 7 July 2020, a total of 192 patients with R/R DLBCL were enrolled in the pola + BR cohort (n = 152 [safety run-in, n = 6; randomized, n = 40; extension cohort, n = 106]) or the BR cohort (n = 40). Significant survival benefit with pola + BR vs BR persisted in the randomized arms . In the extension cohort, the independent review committee-assessed objective response rate was 41.5, and the CR rate was 38.7; median independent review committee-assessed progression-free survival and overall survival were 6.6 mo and 12.5 mo, resp. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group was written by Fujiwara, Yuki;Urata, Tomohiro;Niiya, Daigo;Yano, Tomofumi;Nawa, Yuichiro;Yoshida, Isao;Imai, Toshi;Sunami, Kazutaka;Fujii, Soichiro;Ennishi, Daisuke;Maeda, Yoshinobu;Hiramatsu, Yasushi. And the article was included in International Journal of Hematology in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:

Progression-free survival in patients with untreated follicular lymphoma (FL) has significantly improved with obinutuzumab plus chemotherapy followed by obinutuzumab maintenance, compared with rituximab plus chemotherapy. However, the survival outcome and adverse event profile in Japanese FL patients treated with obinutuzumab plus bendamustine (GB) therapy are not well investigated. Recently, we encountered some cases of grade 3-4 thrombocytopenia during GB therapy in patients with FL. This retrospective multicenter survey aimed to identify the characteristics of patients who received GB therapy and developed thrombocytopenia. A total of 54 patients with FL treated by GB therapy between August 2018 and Dec. 2020 were investigated. After a median follow-up of 12.6 mo, thrombocytopenia of any grade was observed in 48 (88.9%) patients, including 9 (16.7%) patients with grade 3-4 thrombocytopenia. Notably, although eight of nine patients with grade 3-4 thrombocytopenia were female, no patient characteristics (including gender) were significantly associated with grade 3-4 thrombocytopenia. Importantly, grade 3-4 thrombocytopenia frequently occurred in the first GB therapy cycle, which suggests that platelet count should be monitored carefully in patients who have just started GB therapy. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Computed Properties of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Prazoles targeting Tsg101 inhibit release of epstein-barr virus following reactivation from latency was written by Mannemuddhu, Sai Sudha;Xu, Huanzhou;Bleck, Christopher K. E.;Tjandra, Nico;Carter, Carol;Bhaduri-McIntosh, Sumita. And the article was included in Journal of Virology in 2021.Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus responsible for several diseases, including cancers of lymphoid and epithelial cells. EBV cancers typically exhibit viral latency; however, the production and release of EBV through its lytic phase are essential for cancer development. Antiviral agents that specifically target EBV production do not currently exist. Previously, we reported that the proton pump inhibitor tenatoprazole, which blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV. Here, we show that three structurally distinct prazoles impair mature particle formation postreactivation and identify the impact on stages of replication. The prazoles did not impair expression of lytic genes representative of the different kinetic classes but interfered with capsid maturation in the nucleus as well as virion transport from the nucleus. Replacement of endogenous Tsg101 with a mutant Tsg101 refractory to prazole-mediated inhibition rescued EBV release. These findings directly implicate Tsg101 in EBV nuclear egress and identify prazoles as potential therapeutic candidates for conditions that rely on EBV replication, such as chronic active EBV infection and posttransplant lymphoproliferative disorders. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effect of quadruple therapy on Hp eradication rate and gastrin level in patients with Helicobacter pylori-positive chronic superficial gastritis was written by Yan, Jin-he. And the article was included in Xiandai Zhenduan Yu Zhiliao in 2021.Application of 117976-90-6 The following contents are mentioned in the article:

Objective: To investigate the effect of quadruple therapy on Hp eradication rate and gastrin (GAS) level in patients with Helicobacter pylori (Hp) pos. chronic superficial gastritis. Methods: A total of 74 patients with Hp-pos. chronic superficial gastritis admitted to our hospital from August 2018 to Oct. 2019 were selected and divided into the control group and the observation group with 37 cases in each group according to the random number table method. The observation group was treated with rabeprazole sodium quadruple therapy, and the control group was treated with omeprazole quadruple therapy. After 6 wk of treatment, the Hp eradication rates, GAS levels and adverse reactions were compared between the two groups. Results: The eradication rate of Hp in the observation group was higher than that in the control group (P < 0.05). After 6 wk of treatment, the GAS levels in both groups were lower than those before treatment, and the observation group was significantly lower than the control group (P < 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05). Conclusion: Rabeprazole sodium quadruple therapy can improve Hp eradication rate and GAS level in Hp-pos. chronic superficial gastritis patients with good safety. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem